^
CANCER:

Esophageal Squamous Cell Carcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
PD-L1 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive
:
A1
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive
:
B
PD-L1 expression
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
B
PD-L1 expression
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive
:
B
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
B
NTRK3 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C1
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive
:
C1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
camrelizumab
Sensitive
:
C2
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C2
EGFR overexpression
Esophageal Squamous Cell Carcinoma
Z650
Sensitive
:
C2
PD-L1 expression
Esophageal Squamous Cell Carcinoma
toripalimab
Sensitive
:
C2
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive
:
C3
NDRG1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant
:
C3
SGK1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant
:
C3
AFAP1-AS1 overexpression
Esophageal Squamous Cell Carcinoma
FP
Resistant
:
C3
TLR signature
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
C3
NDRG1-H
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab + DKN-01
Sensitive
:
C3
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
DKN-01
Sensitive
:
C3
NFKB1 expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive
:
C3
KDR expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive
:
C3
PD-L1 overexpression + CCL5 overexpression
Esophageal Squamous Cell Carcinoma
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive
:
C3